Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Common Equity: 2013-2024

Historic Common Equity for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$489.1 million.

  • ImmunityBio's Common Equity rose 29.54% to -$524.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$524.3 million, marking a year-over-year increase of 29.54%. This contributed to the annual value of -$489.1 million for FY2024, which is 16.68% up from last year.
  • Latest data reveals that ImmunityBio reported Common Equity of -$489.1 million as of FY2024, which was up 16.68% from -$587.0 million recorded in FY2023.
  • In the past 5 years, ImmunityBio's Common Equity ranged from a high of -$118.5 million in FY2020 and a low of -$587.0 million during FY2023.
  • Its 3-year average for Common Equity is -$508.6 million, with a median of -$489.1 million in 2024.
  • In the last 5 years, ImmunityBio's Common Equity slumped by 825.77% in 2020 and then increased by 16.68% in 2024.
  • Over the past 5 years, ImmunityBio's Common Equity (Yearly) stood at -$118.5 million in 2020, then crashed by 105.85% to -$243.9 million in 2021, then crashed by 84.42% to -$449.8 million in 2022, then crashed by 30.49% to -$587.0 million in 2023, then rose by 16.68% to -$489.1 million in 2024.